# Nuclide record ryz101 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/ryz101/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "ryz101" ;
  schema:name "Actinium-225 DOTATATE"@en ;
  schema:description "An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version."@en ;
  schema:url <https://nuclide.cc/drugs/ryz101/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=RYZ101> ;
  nuclide:status "phase-3" ;
  nuclide:modality "Targeted alpha therapy" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/sclc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:companies <https://nuclide.cc/companies/bms/>, <https://nuclide.cc/companies/rayzebio/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06590857/> .